Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9005498 | Clinical Therapeutics | 2005 | 12 Pages |
Abstract
In this post hoc analysis of switchingfrom the antipsychotic olanzapine to risperidone on the prevalence of the metabolic syndrome in high-risk overweight or obese patients with schizophrenia or schizoaffective disorder, the metabolic syndrome was highly prevalent at baseline. Switching from olanza- pine to risperidone was associated with a significant reduction in this prevalence.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
MD Meyer, PhD Pandina, PhD Bossie, MS Turkoz, MD Greenspan,